We investigated the function of LCN2 and the possible molecular mechanism in WMI induced by SAH (atypical and acute) and MS (typical and chronic) to identify therapeutic targets for remyelination and WMI after SAH and other diseases. The gene discussed is LCN2; the disease is myeloid sarcoma.